Nivolumab (PD-1 inhibitor), pembrolizumab (PD-1 inhibitor), and atezolizumab (PD-L1 inhibitor) have been recommended as the common means for HCC systemic treatment by the latest National Comprehensive Cancer Network (NCCN) guideline (Benson et al., 2021). Here, CD274 is linked to hepatocellular carcinoma.